In a paper published in the May 17, 2024, online issue of Cell, investigators from the Duke Human Vaccine Institute reported that a sequence of three immunizations in the HVTN-133 trial was sufficient for the development of heterologous or broadly neutralizing antibodies that protected against several strains of HIV.
Citing the need to protect the public interest, the U.S. Department of Health and Human Services ordered an immediate government-wide funding suspension May 15 of Ecohealth Alliance Inc. while formal debarment proceedings are pending against the New York-based nongovernmental organization.
TFF Pharmaceuticals Inc. has announced it is advancing into preclinical testing multivalent universal influenza vaccine candidates to protect against seasonal and pandemic viruses, in collaboration with Cleveland Clinic.
In a paper published in the May 17, 2024, online issue of Cell, investigators from the Duke Human Vaccine Institute reported that a sequence of three immunizations in the HVTN-133 trial was sufficient for the development of heterologous or broadly neutralizing antibodies (bnAbs) that protected against several strains of HIV. The findings are “a real beachhead,” Barton Haynes told BioWorld. Haynes is the director of the Duke Human Vaccine Institute and the senior author of the paper.
Citing the need to protect the public interest, the U.S. Department of Health and Human Services ordered an immediate government-wide funding suspension May 15 of Ecohealth Alliance Inc. while formal debarment proceedings are pending against the New York-based nongovernmental organization.
Hepaitech (Beijing) Biopharma Technology Co. Ltd. has patented compounds reported to be useful for the treatment of anemia, fungal infections and HIV infections, among others.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have presented compounds reported to be useful for the treatment of gram-negative bacterial infections.
Osaka, Japan-based Shionogi & Co. Ltd. said May 13 that ensitrelvir fumaric acid (Xocova), its oral antiviral for COVID-19, showed no statistical difference against placebo in completely resolving 15 common COVID-19-related symptoms in a global phase III Scorpio-HR trial.
Is the U.S. getting the best return on investment (ROI) for its NIH buck? That’s the basic question at the heart of a white paper Sen. Bill Cassidy (R-La.) issued May 9 to continue a conversation he started in September on the reforms needed at the country’s premier biomedical research institution.
By isolating a single clone from human isolates, researchers from the National Taiwan University College of Medicine aimed to enhance the immunogenicity of the Zika virus (ZIKV).
RSS
